You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Under the terms of the agreement, M3 and G-TAC will promote 14 Pathway tests through G-TAC's personalized medicine platform connected to M3's physician network.
Under the agreement, Genomic Health will make an undisclosed equity investment in Epic Sciences, and will have exclusive rights to market its test in the US.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The deal gives SouthGenetics marketing rights for MDxHealth's ConfirmMDx test for prostate cancer in 12 countries, including Mexico, Argentina, and Colombia.
The deal will provide researchers a fully automated solution for immunostaining captured circulating tumor cells deposited on microscope slides.
The deal provides customers a complete end-to-end solution for cytogenomic array and next-generation sequencing services, the firms said.
The partners will co-market the Phenomenex Strata and Strata-X SPE sorbents adapted to Tecan's Freedom EVO series of robotic workstations.
Under the agreement, customers will be able to purchase GeneSeek Genomic Profiler SNP arrays from Illumina, initially for genotyping cattle, pigs, and horses.
Under the terms of the agreement, Tataa will distribute and support Strand's analysis software in Europe and will also use the tool in training programs.
Thermo Fisher will market Horizon's X-MAN human haploid and diploid isogenic cell line collection.
Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.
The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.
Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.
In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.